Optimizing PBMC Cryopreservation and Utilization for ImmunoSpot® Analysis of Antigen-Specific Memory B Cells
Vaccines · 19.07.2025 · 13 (7) · 765
DOI: 10.3390/vaccines13070765 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 19.07.2025. Verfasst von Noémi Becza und 3 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development, Cellular Technology Ltd. (CTL), Shaker Heights, OH 44122, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: R&D budget of Cellular Technology Limited (CTL).
Abstract (Originalsprache)
Background
Measuring frequencies of antigen-specific memory B cells (Bmem), their immunoglobulin (Ig) class and subclass usage, cross-reactivity, and affinity can provide insights into the efficacy of future antibody responses in case of antigen re-encounter. B cell ImmunoSpot® assays can provide such information; however, like most cell-based tests, they require considerable amounts of blood to be drawn from the donor and this has hindered their inclusion in clinical trials and routine immune diagnostics.
Methods
We introduce strategies for reducing the cell numbers required to 2–3 million peripheral blood mononuclear cells (PBMCs) per antigen, obtainable from 2–3 mL of blood from healthy adult donors.
Results
Except when Bmem frequencies were very low, we found that testing PBMCs in singlet wells, but in serial dilution, enables as reliable Bmem frequency assessments as when testing replicate wells at a single fixed cell number. Additionally, B cell ImmunoSpot® assays can be multiplexed for detecting four Ig classes, or IgG subclasses, simultaneously and without loss of sensitivity. The requirement for low cell numbers and the retention of B cell functionality by cryopreserved PBMCs equivalent to freshly isolated material implies that fewer than the standard 10 million PBMCs per vial can be frozen. This would reduce the number of individuals who could not be tested for Bmem due to insufficient availability of PBMCs, a common problem with such assays.
Conclusions
The predictable need for and recovery of cryopreserved PBMCs facilitates planning of and optimal cell utilization in B cell ImmunoSpot® assays and increases the practical feasibility of extensive Bmem characterization in larger cohorts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research and Development, Cellular Technology Ltd. (CTL), Shaker Heights, OH 44122, USA.
ORCID-Profile: Greg A Kirchenbaum
Förderung
- R&D budget of Cellular Technology Limited (CTL)
Zitieren
APA
Becza, N., Yao, L., Lehmann, P. V., & Kirchenbaum, G. A. (2025). Optimizing PBMC Cryopreservation and Utilization for ImmunoSpot® Analysis of Antigen-Specific Memory B Cells. Vaccines, 13(7), 765. https://doi.org/10.3390/vaccines13070765
Vancouver
Becza N, Yao L, Lehmann PV, Kirchenbaum GA. Optimizing PBMC Cryopreservation and Utilization for ImmunoSpot® Analysis of Antigen-Specific Memory B Cells. Vaccines. 2025;13(7):765. doi:10.3390/vaccines13070765
BibTeX
@article{Becza2025,
author = {Becza, Noémi and Yao, Lingling and Lehmann, Paul V and Kirchenbaum, Greg A},
title = {Optimizing PBMC Cryopreservation and Utilization for ImmunoSpot® Analysis of Antigen-Specific Memory B Cells},
journal = {Vaccines},
year = {2025},
volume = {13},
number = {7},
pages = {765},
doi = {10.3390/vaccines13070765}
}
EUVIMED